TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Benzinga Logo Benzinga By Vandana Singh
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.

Insights
JNJ   positive

Positive Phase 2b trial results for nipocalimab meeting primary and key secondary endpoints with favorable safety profile; company advancing to Phase 3 development